Overview
UK veterinary sales firm estimates FY25 revenue grew 20%, slightly missing analyst expectations
Company estimates FY25 underlying EBITDA growth, in line with company-provided market expectations of £17.6 mln
Company strengthened R&D pipeline and made strategic equity investment in InVetro Pty Ltd
Outlook
Animalcare plans to invest 5% of revenue in R&D from 2026
Company aims to leverage commercial platform for sustainable growth
Animalcare to host Capital Markets Event in March to discuss growth strategies
Result Drivers
RANDLAB INTEGRATION - Successful integration of Randlab contributed significantly to revenue and EBITDA growth, supported by high gross margins
COMPANION ANIMAL GROWTH - Strong double-digit growth in flagship brands like Daxocox, aided by new tablet strengths
EQUINE SEGMENT EXPANSION - Equine products saw strong growth, now representing 24% of revenues, driven by Randlab's contribution and organic growth
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
FY Revenue
Slight Miss*
GBP 89.1 mln
GBP 89.23 mln (4 Analysts)
*Applies to a deviation of less than 1%; not applicable for per-share numbers.
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Animalcare Group plc is GBp332.50, about 30.9% above its January 21 closing price of GBp254.00
The stock recently traded at 17 times the next 12-month earnings vs. a P/E of 16 three months ago
Press Release: ID:nRSV8630Pa
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)